Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?

Ever since its outbreak in December 2019, novel coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread to more than 200 nations, affecting over 509,000 individuals and inflicting over 23,000 fatalities globally [1]. Although the overall mortality rate is low, ranging from 1.4%-7.2%, people with diabetes mellitus (DM) tend to have more severe disease, acute respiratory distress syndrome and increased fatality [2,3]. Of the 1099 confirmed COVID-19 patients reported from China, 173 had severe disease; DM was more prevalent in those with severe disease (16.2%) as compared to those with non-severe disease (5.7%) [2].
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Tags: Commentary Source Type: research